Editas Medicine released a tiny drop of data last year as a proof of concept for its gene editing platform. Now, the CRISPR/Cas9 biotech will spend 2022 trying to back that up. We’re going to hear ...

Editas Medicine said today its lead candidate EDIT-101, an in vivo CRISPR gene editing treatment for Leber congenital amaurosis-10 (LCA10), showed positive initial clinical data showing it to be safe, ...

1Spatial has launched 1Edit, a touchscreen compatible solution that offers fast and intuitive data-editing in the field or office, 1Spatial said. Trialed by Ordnance Survey Ireland (OSi), 1Edit ...

Editas Medicine (EDIT) reported in vivo preclinical proof-of-concept data for EDIT-401, an experimental, one-time therapy to significantly reduce ...

Whether your screen is made up of your personal favorite data points or are imported from Morningstar’s pre-defined screens, you can control the data you see and the order in which columns are ...

Knowing how to customize the contents of your Garmin watch’s data screens is essential if you want to vary the information and insights you see during workouts. No matter which Garmin sports watch you ...

Chroma Medicine highlighted data demonstrating the advantages of epigenetic editing for multiplex gene regulation at the American Society of Gene & Cell Therapy (ASGCT) 26 th Annual Meeting in Los ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a next-generation cardiovascular company, today announced the presentation of new preclinical proof-of-concept data in non-human primates that ...